KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Return on Sales: 2009-2025

Historic Return on Sales for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to 0.17%.

  • Biomarin Pharmaceutical's Return on Sales rose 5.00% to 0.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.17%, marking a year-over-year increase of 5.00%. This contributed to the annual value of 0.15% for FY2024, which is 8.00% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Return on Sales stood at 0.17% for Q3 2025, which was down 21.60% from 0.21% recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Return on Sales peaked at 0.43% during Q2 2021, and registered a low of -0.03% during Q4 2021.
  • Moreover, its 3-year median value for Return on Sales was 0.10% (2024), whereas its average is 0.11%.
  • Data for Biomarin Pharmaceutical's Return on Sales shows a peak YoY increase of 37bps (in 2021) and a maximum YoY decrease of 49bps (in 2021) over the last 5 years.
  • Biomarin Pharmaceutical's Return on Sales (Quarterly) stood at -0.03% in 2021, then climbed by 10bps to 0.07% in 2022, then remained steady at 0.07% in 2023, then grew by 8bps to 0.15% in 2024, then increased by 5bps to 0.17% in 2025.
  • Its Return on Sales was 0.17% in Q3 2025, compared to 0.21% in Q2 2025 and 0.18% in Q1 2025.